Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis

被引:94
作者
Di Stefano, V
Rinaldo, C
Sacchi, A
Soddu, S
D'Orazi, G
机构
[1] Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00158 Rome, Italy
[2] Univ G dAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy
关键词
HIPK2; serine-threonine kinase; kinase inhibitor SB203580; RNAi; cisplatin; antineoplastic drug; p53; phosphorylation; apoptosis;
D O I
10.1016/j.yexcr.2003.09.032
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HIPK2 is a member of a novel family of nuclear serine-threonine kinases identified through their ability to interact with the Nkx-1.2 homeoprotein. The physiological role of these kinases is largely unknown, but we have recently reported on the involvement of HIPK2 in the induction of apoptosis of tumor cells after UV stress through p53 phosphorylation and transcriptional activation. Here, we demonstrate that the chemotherapeutic drug cisplatin increases HIPK2 protein expression and its kinase activity, and that HIPK2 is involved in cisplatin-dependent apoptosis. Indeed, induction of HIPK2 and of cell death by cisplatin are efficiently inhibited by the serine-threonine kinase inhibitor SB203580 or the transduction of HIPK2-specific RNA-interfering molecules. HIPK2 gene silencing efficiently reduces the p53-mediated transcriptional activation of apoptotic gene promoters as well as apoptotic cell death after treatment with cisplatin. These findings, along with the involvement of p53 phosphorylation at serine 46 (Ser46) in the transcriptional activation of apoptotic gene promoters, suggest a critical role for HIPK2 in triggering p53-dependent apoptosis in response to the antineoplastic drug cisplatin. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:311 / 320
页数:10
相关论文
共 40 条
[11]  
Fink D, 1997, CANCER RES, V57, P1841
[12]   p63 and p73 are required for p53-dependent apoptosis in response to DNA damage [J].
Flores, ER ;
Tsai, KY ;
Crowley, D ;
Sengupta, S ;
Yang, A ;
McKeon, F ;
Jacks, T .
NATURE, 2002, 416 (6880) :560-564
[13]   The complexity of p53 modulation: emerging patterns from divergent signals [J].
Giaccia, AJ ;
Kastan, MB .
GENES & DEVELOPMENT, 1998, 12 (19) :2973-2983
[14]   Cellular stress response and apoptosis in cancer therapy [J].
Herr, I ;
Debatin, KM .
BLOOD, 2001, 98 (09) :2603-2614
[15]   Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2 [J].
Hofmann, TG ;
Möller, A ;
Sirma, H ;
Zentgraf, H ;
Taya, Y ;
Dröge, W ;
Will, H ;
Schmitz, ML .
NATURE CELL BIOLOGY, 2002, 4 (01) :1-10
[16]   Human homeodomain-interacting protein kinase-2 (HIPK2) is a member of the DYRK family of protein kinases and maps to chromosome 7q32-q34 [J].
Hofmann, TG ;
Mincheva, A ;
Lichter, P ;
Dröge, W ;
Schmitz, ML .
BIOCHIMIE, 2000, 82 (12) :1123-1127
[17]   Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo [J].
Kim, EJ ;
Park, JS ;
Um, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) :32020-32028
[18]   Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors [J].
Kim, YH ;
Choi, CY ;
Lee, SJ ;
Conti, MA ;
Kim, Y .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (40) :25875-25879
[19]   Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1 [J].
Kim, YH ;
Choi, CY ;
Kim, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (22) :12350-12355
[20]  
Lippert B., 1999, CISPLATIN CHEM BIOCH